CN114729007A - 麻疹的联合抗病毒治疗 - Google Patents

麻疹的联合抗病毒治疗 Download PDF

Info

Publication number
CN114729007A
CN114729007A CN202080077668.XA CN202080077668A CN114729007A CN 114729007 A CN114729007 A CN 114729007A CN 202080077668 A CN202080077668 A CN 202080077668A CN 114729007 A CN114729007 A CN 114729007A
Authority
CN
China
Prior art keywords
peptide
hrc
fip
antiviral
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080077668.XA
Other languages
English (en)
Chinese (zh)
Inventor
M·波罗托
A·莫斯科纳
C·阿拉比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Cornell University
Original Assignee
Columbia University in the City of New York
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York, Cornell University filed Critical Columbia University in the City of New York
Publication of CN114729007A publication Critical patent/CN114729007A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18433—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080077668.XA 2019-09-04 2020-09-04 麻疹的联合抗病毒治疗 Pending CN114729007A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962895752P 2019-09-04 2019-09-04
US62/895,752 2019-09-04
US202062988286P 2020-03-11 2020-03-11
US62/988,286 2020-03-11
US202063009883P 2020-04-14 2020-04-14
US63/009,883 2020-04-14
PCT/US2020/049473 WO2021046398A2 (en) 2019-09-04 2020-09-04 Combination antiviral therapy for measles

Publications (1)

Publication Number Publication Date
CN114729007A true CN114729007A (zh) 2022-07-08

Family

ID=74853434

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080077668.XA Pending CN114729007A (zh) 2019-09-04 2020-09-04 麻疹的联合抗病毒治疗

Country Status (6)

Country Link
US (1) US20230014151A1 (https=)
EP (1) EP4025586A4 (https=)
JP (1) JP2022551813A (https=)
CN (1) CN114729007A (https=)
IL (1) IL291091A (https=)
WO (1) WO2021046398A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159372A1 (en) * 2021-01-22 2022-07-28 Decoy Therapeutics, Inc. Methods and compositions for treating infections
WO2023150375A2 (en) * 2022-02-07 2023-08-10 Decoy Therapeutics Inc. Methods and compositions for treating covid infections
WO2025085916A1 (en) * 2023-10-20 2025-04-24 The Trustees Of Columbia University In The City Of New York Humanized monoclonal antibody and vaccines against measles virus
WO2025111546A1 (en) * 2023-11-22 2025-05-30 Board Of Trustees Of Michigan State University Development of broad-spectrum anti-opioid vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280754A1 (en) * 2003-11-04 2006-12-14 Garry Robert F Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins
US20170216448A1 (en) * 2014-05-07 2017-08-03 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687911A (zh) * 2007-05-16 2010-03-31 康久化学生物技术公司 抗病毒肽的半胱磺酸衍生物
WO2012020108A2 (en) * 2010-08-11 2012-02-16 Cormus Srl Multimeric inhibitors of viral fusion and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280754A1 (en) * 2003-11-04 2006-12-14 Garry Robert F Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins
US20170216448A1 (en) * 2014-05-07 2017-08-03 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENNIS HOFFMANN;WIBKE BAYER;OLIVER WILDNER;: "In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines", WORLD JOURNAL OF GASTROENTEROLOGY, no. 22, 14 June 2007 (2007-06-14) *
TIAGO N. FIGUEIRA, ET AL: "Structure-Stability-Function Mechanistic Links in the Anti-Measles Virus Action of Tocopherol-Derivatized Peptide Nanoparticles", ACS NANO, vol. 12, no. 10, 19 September 2018 (2018-09-19), pages 1, XP093100901, DOI: 10.1021/acsnano.8b01422 *

Also Published As

Publication number Publication date
WO2021046398A2 (en) 2021-03-11
JP2022551813A (ja) 2022-12-14
US20230014151A1 (en) 2023-01-19
EP4025586A4 (en) 2024-01-03
IL291091A (en) 2022-05-01
WO2021046398A3 (en) 2021-04-08
EP4025586A2 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
US12269155B2 (en) Multivalent vaccines for rabies virus and coronaviruses
CN114729007A (zh) 麻疹的联合抗病毒治疗
US20240400651A1 (en) Neutralizing monoclonal antibodies against covid-19
JP7554837B2 (ja) 可溶性ａｃｅ２及び融合タンパク質、並びにその適用
AU2004230485A1 (en) The severe acute respiratory syndrome coronavirus
TWI894291B (zh) 用於治療及預防SARS-CoV-2感染的人源化ACE2-Fc融合蛋白
EA017957B1 (ru) Композиции и способы, ингибирующие грипп
WO2023020623A1 (zh) 用于预防或治疗冠状病毒感染的融合蛋白、Spike蛋白纳米颗粒及其应用
US12440552B2 (en) Methods for immunizing pre-immune subjects against respiratory syncytial virus (RSV)
WO2022051859A1 (en) Pseudotyped retroviral particles for inducing immunity against coronavirus infections
WO2023201304A2 (en) Compositions for preventing or treating coronavirus infections
TW201545755A (zh) 重組呼吸道融合病毒及疫苗
CN115772227A (zh) 新型冠状病毒SARS-CoV-2的Delta变异株疫苗与应用
JP2023540705A (ja) 修飾された抗ウイルス結合剤
TW202539697A (zh) 冠狀病毒疫苗
WO2024229151A2 (en) Multimeric coronavirus binding molecules and uses thereof
US20060110740A1 (en) Use of sendai virus as a human parainfluenza vaccine
US20240101629A1 (en) Use of interleukin-7 for the treatment of coronavirus
JP2024502783A (ja) コロナウイルスワクチン
US11186626B2 (en) Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
WO2005063798A1 (en) Identification of two linear epitopes on ebola or marburg virus glycoproteins critical for infection
WO2024061188A1 (zh) 一种冠状病毒多价疫苗及其应用
Navaratnarajah Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins
WO2024196683A2 (en) Vsv-based sars-cov-2 vaccine candidates and igy antibodies as prophylactic and therapeutic agents against sars-cov-2 and variants of concern
CN105431526A (zh) 免疫原性组合物及其产生方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220708

WD01 Invention patent application deemed withdrawn after publication